Marksans Pharma Limited (NSE:MARKSANS)
India · Delayed Price · Currency is INR 178.00
-3.15 (-1.74%)
Feb 19, 2026, 2:10 PM IST
Marksans Pharma Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Operating Revenue | 28,033 | 26,228 | 21,774 | 18,521 | 14,908 | 13,762 |
| 28,033 | 26,228 | 21,774 | 18,521 | 14,908 | 13,762 | |
Revenue Growth (YoY) | 13.29% | 20.46% | 17.56% | 24.23% | 8.33% | 21.32% |
Cost of Revenue | 12,662 | 11,981 | 10,740 | 9,401 | 7,295 | 6,056 |
Gross Profit | 15,371 | 14,247 | 11,034 | 9,120 | 7,613 | 7,706 |
Selling, General & Admin | 4,231 | 3,620 | 3,059 | 2,523 | 2,250 | 2,096 |
Other Operating Expenses | 5,857 | 5,341 | 3,389 | 3,202 | 2,774 | 2,204 |
Operating Expenses | 11,059 | 9,795 | 7,191 | 6,243 | 5,472 | 4,614 |
Operating Income | 4,311 | 4,452 | 3,843 | 2,877 | 2,141 | 3,092 |
Interest Expense | -212.49 | -116.6 | -112.03 | -60.96 | -57.4 | -38.17 |
Interest & Investment Income | 301.97 | 301.97 | 337.87 | 120.37 | 59.73 | 11.59 |
Currency Exchange Gain (Loss) | 233.58 | 233.58 | 82.4 | 397.77 | 205.79 | -9.67 |
Other Non Operating Income (Expenses) | 124.93 | 161.27 | 82.1 | 44.67 | 124.79 | 13.29 |
EBT Excluding Unusual Items | 4,759 | 5,032 | 4,233 | 3,379 | 2,474 | 3,069 |
Impairment of Goodwill | - | - | - | - | - | -47.9 |
Gain (Loss) on Sale of Investments | 6.94 | 6.94 | 0.52 | - | - | - |
Gain (Loss) on Sale of Assets | 0.33 | 0.33 | 0.94 | -2.64 | - | 0.3 |
Pretax Income | 4,767 | 5,040 | 4,235 | 3,377 | 2,475 | 3,022 |
Income Tax Expense | 1,149 | 1,213 | 1,086 | 723.32 | 606.97 | 636.26 |
Earnings From Continuing Operations | 3,618 | 3,826 | 3,149 | 2,653 | 1,868 | 2,385 |
Minority Interest in Earnings | -14.43 | -20.44 | -11.95 | 9.87 | - | - |
Net Income | 3,603 | 3,806 | 3,137 | 2,663 | 1,868 | 2,385 |
Net Income to Common | 3,603 | 3,806 | 3,137 | 2,663 | 1,868 | 2,385 |
Net Income Growth | -2.17% | 21.32% | 17.80% | 42.55% | -21.68% | 97.54% |
Shares Outstanding (Basic) | 453 | 453 | 453 | 415 | 409 | 409 |
Shares Outstanding (Diluted) | 453 | 453 | 453 | 415 | 409 | 409 |
Shares Change (YoY) | 0.10% | - | 9.09% | 1.49% | - | -0.00% |
EPS (Basic) | 7.95 | 8.40 | 6.92 | 6.41 | 4.56 | 5.83 |
EPS (Diluted) | 7.95 | 8.40 | 6.92 | 6.41 | 4.56 | 5.83 |
EPS Growth | -2.25% | 21.36% | 7.96% | 40.44% | -21.68% | 97.54% |
Free Cash Flow | - | 337.45 | 215.69 | 1,838 | 529.27 | 1,322 |
Free Cash Flow Per Share | - | 0.74 | 0.48 | 4.42 | 1.29 | 3.23 |
Dividend Per Share | - | 0.800 | 0.600 | 0.500 | 0.250 | 0.250 |
Dividend Growth | - | 33.33% | 20.00% | 100.00% | - | 150.00% |
Gross Margin | 54.83% | 54.32% | 50.67% | 49.24% | 51.07% | 56.00% |
Operating Margin | 15.38% | 16.98% | 17.65% | 15.53% | 14.36% | 22.47% |
Profit Margin | 12.85% | 14.51% | 14.41% | 14.38% | 12.53% | 17.33% |
Free Cash Flow Margin | - | 1.29% | 0.99% | 9.92% | 3.55% | 9.60% |
EBITDA | 4,922 | 5,013 | 4,337 | 3,203 | 2,405 | 3,351 |
EBITDA Margin | 17.56% | 19.11% | 19.92% | 17.30% | 16.13% | 24.35% |
D&A For EBITDA | 610.35 | 560.56 | 494.18 | 326.09 | 263.46 | 258.82 |
EBIT | 4,311 | 4,452 | 3,843 | 2,877 | 2,141 | 3,092 |
EBIT Margin | 15.38% | 16.98% | 17.65% | 15.53% | 14.36% | 22.47% |
Effective Tax Rate | 24.10% | 24.08% | 25.65% | 21.42% | 24.52% | 21.06% |
Revenue as Reported | 28,700 | 26,932 | 22,278 | 19,115 | 15,327 | 13,829 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.